Successful inhibition of the N-Myc-Max complex formation has shown to be an effective therapeutic strategy [25]; however, there are currently no clinically-approved compounds that were designed to interact directly with the N-Myc-Max DBD to treat PCa. The gene discussed is MYCN; the disease is posterior cortical atrophy.